---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-077880"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2025-05-28T23:59:59+00:00"
generated_at: "2026-05-20T08:11:48.672216+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics stockholders approve reverse stock split amendment at 2025 annual meeting

## Summary
- Reverse stock split amendment approved: 20,983,236 votes for, 3,224,611 against (86.9% of votes cast).
- Laura Berner and Brian O'Callaghan elected as Class I directors with 10.6M and 11.2M votes for, respectively.
- PricewaterhouseCoopers LLP ratified as independent auditor for FY2025: 23,330,316 votes for.
- Annual meeting had 24,362,318 shares represented out of 38,339,697 entitled to vote.

## SEC filing metadata
- accession: 0000950170-25-077880
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2025-05-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000095017025077880/0000950170-25-077880-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000095017025077880/bolt-20250527.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-077880
- JSON: https://secwatch.observer/filing/0000950170-25-077880.json
- Plain text: https://secwatch.observer/filing/0000950170-25-077880.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.